This comprehensive review explores how liquid biopsies—blood tests analyzing tumor-derived materials—are revolutionizing care for triple-negative breast cancer (TNBC). Key findings show that circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) can predict treatment response, detect cancer recurrence earlier than imaging, and guide personalized therapy. For example, patients with ≥5 CTCs per 7.5ml of blood had significantly worse survival (22.4% recurrence rate post-surgery), while ctDNA clearance after chemotherapy correlated with 100% pathologic complete response. Ongoing clinical trials are actively validating these biomarkers for real-time monitoring and targeted treatment selection.

Liquid Biopsy in Triple-Negative Breast Cancer: A New Era of Personalized Treatment

Table of Contents

• Introduction: Why TNBC Needs Better Tools
• What is Liquid Biopsy?
• CTCs in Early-Stage TNBC
• CTCs in Metastatic TNBC
• ctDNA in Early-Stage TNBC
• Ongoing Clinical Trials
• Key Research Findings
• What This Means for Patients
• Current Limitations
• Patient Recommendations

Introduction: Why TNBC Needs Better Tools

Triple-negative breast cancer (TNBC) lacks estrogen receptors, progesterone receptors, and HER2 protein, making up 10%-15% of all breast cancers. It's more aggressive and common in women under 40. Current biomarkers like PD-L1 protein expression (found in 20%-38% of metastatic cases) and tumor-infiltrating lymphocytes (TILs) have limitations. High TIL levels correlate with better outcomes—especially when present inside tumors rather than just margins—but we need more precise tools. Liquid biopsies offer a promising solution by detecting cancer signals in blood, potentially guiding treatment decisions for early and metastatic TNBC.

What is Liquid Biopsy?

Liquid biopsy analyzes tumor-derived materials in blood, urine, or other fluids. Key components include:

Circulating Tumor Cells (CTCs): Whole cancer cells shed from tumors. Having ≥5 CTCs per 7.5ml of blood indicates aggressive disease.

Circulating Tumor DNA (ctDNA): Fragments of tumor DNA with a short half-life (16 minutes to 2.5 hours), providing real-time tumor snapshots.

Other biomarkers: Exosomes (tiny message-carrying vesicles), tumor-related RNA, and immune markers. These help detect recurrence early, monitor treatment response, and identify therapeutic targets.

CTCs in Early-Stage TNBC

Studies show CTCs powerfully predict recurrence risk after initial treatment:

- In the SUCCESS A trial (1,087 high-risk patients), CTCs detected 2 years post-chemotherapy independently predicted worse survival. Patients positive at both baseline and 2 years had the worst outcomes.

- Another study of 286 TNBC patients found >5 CTCs per 7.5ml blood after surgery correlated with 22.4% recurrence rate within 7 days.

- During neoadjuvant chemotherapy (NAC), CTC presence after treatment completion signaled decreased overall survival. A meta-analysis of 2,030 patients (25.8% TNBC) confirmed CTCs' prognostic value regardless of cancer subtype.

CTCs in Metastatic TNBC

CTC levels stratify metastatic TNBC into two groups:

Stage IV Indolent: <5 CTCs per 7.5ml blood → Longer median survival
Stage IV Aggressive: ≥5 CTCs → Poor prognosis

Key findings:

- Patients with CTC clusters (multiple cells stuck together) have 20-100x higher metastasis risk than those with single CTCs.

- In 32 stage III/IV TNBC patients, 42% had CTCs showing hybrid epithelial-mesenchymal transition (EMT) status—a cellular change linked to treatment resistance and spread.

- CTC analysis can reveal targetable mutations like PIK3CA. In one study, 6 of 39 metastatic breast cancer patients had PIK3CA mutations detectable only in CTCs, not in original tumors.

ctDNA in Early-Stage TNBC

ctDNA detects minimal residual disease (MRD)—hidden cancer cells after treatment:

- The Q-CROC-03 trial showed rising ctDNA during NAC predicted incomplete response to chemo. Patients with undetectable ctDNA post-treatment had relapse-free survival similar to those achieving pathologic complete response (pCR).

- In the I-SPY 2 trial, 73% of TNBC patients had detectable ctDNA before NAC. Those remaining positive at 3 weeks had 83% residual disease vs. 52% in those who cleared ctDNA. All pCR patients were ctDNA-negative.

- ctDNA positivity before surgery increased relapse risk, suggesting these patients may need treatment intensification.

Ongoing Clinical Trials

Over 15 trials are validating liquid biopsy applications:

Early-Stage TNBC (Table 1):
- NCT04768426: Monitoring ctDNA during adjuvant capecitabine in 5-year study.
- NCT04849364 (PERSEVERE): Assigning post-NAC therapy based on ctDNA/genomic markers (13-year study).
- NCT03872388: Using CTCs to evaluate atorvastatin’s effect in non-pCR patients (4-year study).

Metastatic TNBC (Table 2):
- NCT05266937: Tracking ctDNA changes during first-line chemo/immunotherapy (4-year trial).
- NCT04251533 (EPIK-B3): Targeting PIK3CA mutations identified by ctDNA (7-year trial).
- NCT04837209 (NADiR): Monitoring ctDNA during niraparib/dostarlimab/radiotherapy (8-year study).

Key Research Findings

1. CTC Threshold: ≥5 CTCs/7.5ml blood predicts aggressive disease in both early (22.4% recurrence) and metastatic TNBC.

2. ctDNA Clearance: Undetectable ctDNA after neoadjuvant chemo correlates with 100% pathologic complete response and superior long-term outcomes.

3. Early Detection: Rising ctDNA during treatment predicts residual disease with 83% accuracy (I-SPY 2).

4. Molecular Insights: CTC analysis reveals targetable mutations (e.g., PIK3CA) and resistance mechanisms like EMT transition.

5. Prognostic Stratification: Liquid biopsy identifies high-risk patients who may benefit from treatment escalation.

What This Means for Patients

1. Personalized Monitoring: Blood tests may soon replace invasive biopsies for tracking treatment response and recurrence risk.

2. Early Intervention: Detecting molecular relapse months before scans allows earlier therapeutic adjustments.

3. Therapy Selection: CTC/ctDNA analysis can identify patients for targeted therapies (e.g., PARP inhibitors for BRCA mutations).

4. Reduced Overtreatment: Patients with negative liquid biopsies may avoid unnecessary aggressive therapies.

5. Real-Time Adaptation: Monitoring clonal evolution during therapy helps combat emerging resistance.

Current Limitations

1. Detection Sensitivity: Current technologies may miss very low levels of CTCs or ctDNA.

2. Technical Variability: Different platforms (e.g., CELLSEARCH vs. IE/FC) yield slightly different CTC counts.

3. Clinical Utility: While prognostic value is established, predictive value for treatment guidance needs validation in ongoing trials.

4. Spatial Heterogeneity: Liquid biopsy may not fully capture tumor diversity across different sites.

5. Standardization: Lack of uniform thresholds (e.g., CTC counts) and methodology across centers.

Patient Recommendations

1. Discuss Testing Options: Ask your oncologist about liquid biopsy availability for treatment monitoring.

2. Clinical Trial Participation: Consider enrolling in trials like PERSEVERE (NCT04849364) or EPIK-B3 (NCT04251533).

3. Interpret Results Contextually: Liquid biopsy data should complement—not replace—imaging and clinical assessment.

4. Advocate for Biomarker Testing: Request PD-L1, BRCA, and TIL status testing alongside liquid biopsies.

5. Stay Informed: Follow updates on FDA approvals for liquid biopsy platforms like CELLSEARCH.